1. Characterization of autoantibodies and cytokines related to cutaneous lupus erythematosus
- Author
-
Yu-ping Zhang, Guo-zhen Tan, Liangchun Wang, Zengqi Tang, Jing Yin, Feng-Qiu Hu, Yanfang Han, and Zhenrui Shi
- Subjects
Adult ,Male ,Severity of Illness Index ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Lupus Erythematosus, Discoid ,Rheumatology ,Interferon ,medicine ,Lupus Erythematosus, Cutaneous ,Humans ,Lupus Erythematosus, Systemic ,Autoantibodies ,Skin ,030203 arthritis & rheumatology ,biology ,business.industry ,Interleukin-17 ,Autoantibody ,Immunohistochemistry ,Case-Control Studies ,Immunology ,Cutaneous Lupus Erythematosus ,biology.protein ,Female ,Interleukin 17 ,Interferons ,Antibody ,business ,Cutaneous lupus ,medicine.drug - Abstract
Objective To investigate the profiles of anti-RPLP0, anti-galectin3 antibodies, interferon-α (IFN-α), interferon-λ1(IFN-λ1) and interleukin-17A/F(IL-17A/F) in the subtypes of cutaneous lupus erythematosus (CLE) including acute CLE (ACLE), subacute CLE (SCLE) and discoid lupus erythematosus (DLE). Methods Serum levels of autoantibodies and cytokines were determined by enzyme-linked immunoabsorbent assay (ELISA). Lupus lesions were evaluated by cutaneous lupus erythematosus disease area and severity index (CLASI). Results Serum anti-RPLP0, anti-galectin3 antibodies and IFN-λ1 were higher in systemic lupus erythematosus (SLE) patients with skin lesions than those without skin lesions, compared to healthy controls. IFN-α, IL-17A and IL-17F was elevated in all patients regardless of skin lesions. The two antibodies, IFN-α and IL-17A were positively correlated with the CLASI score in all patients with CLE. In addition, serum IL-17A was positively correlated to the CLASI score of ACLE, SCLE and DLE, while anti-RPLP0 and anti-galectin3 antibodies were only correlated to the score of SCLE and IL-17F to DLE. Conclusion Serum anti-RPLP0, anti-galectin3 antibodies, IFN-α, IFN-λ1 and IL-17A/F are associated with the occurrence of lupus skin lesions regardless of the systemic complications, whereas the profiles of these inflammatory mediators vary with the subtypes of lupus skin lesions.
- Published
- 2020